UNITED LAB (03933): UBT48128 has received clinical trial approval from the FDA in the United States.

United Lab (03933) announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has independently developed a Class 1 innovative drug, UBT48128 tablets, and has received approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application concerning indications for overweight or obesity and type 2 diabetes. The IND numbers are 182060 and 182061, respectively. UBT48128 tablets are a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist that promotes insulin secretion while controlling appetite and adjusting energy metabolism, thereby reducing blood glucose levels and aiding weight loss. Preclinical studies in various animal models have shown that UBT48128 can significantly reduce weight and blood glucose levels, with a weight loss effect superior to currently marketed similar products. It is expected that this product will demonstrate promising therapeutic benefits for overweight or obesity and type 2 diabetes. In the future, the company will continue to focus on the development of new products, enhancing its competitiveness and creativity in the biopharmaceutical industry, and deepening its involvement in the management of chronic diseases, with the aim of providing high-quality products and comprehensive pipeline services to benefit patients, thereby creating greater returns for the company and its shareholders.